The Trump administration "will take a look" after billionaire investor Peter Thiel said the FBI and CIA should see if Chinese intelligence has infiltrated Google.Technologyread more
On Monday, the first day of Amazon's 48-hour shopping extravaganza this year, retailers that make more than $1 billion in annual revenues saw a 64% increase in their digital...Retailread more
Builder confidence for single-family homes rose just one point to 65 in July, according to the National Association of Home Builders/Wells Fargo Housing Market Index (HMI)....Real Estateread more
Dimon is making his own bet on a digital coin that could transform the global payments landscape: JPM Coin.Financeread more
Expectations for lower interest rates and less fear about tariffs sent investors back into the market and set up what could be a profitable run ahead.Marketsread more
Southwest Airlines is delaying pilot hiring and captain upgrades with no end in sight to the grounding of the Boeing 737 Max.Airlinesread more
The U.S. and China have restarted their trade talks, but signs are showing a deal could be even harder to reach now.Marketsread more
The Federal Reserve's expected interest rate cuts appears to have impacted J.P. Morgan's forecast for 2019 net interest income.Financeread more
A crop of long-awaited technology companies coming to the public market this year created a "frothy" period, Bernstein said on TuesdayInvestingread more
GE hasn't had a year this good during this millennium. After that massive surge, one trader is warning investors to stay away.Trading Nationread more
Credit card sales volume rose 11% this quarter and merchant processing volume increased 12%, the bank says in its earnings statement.Banksread more
Gottlieb resigned from the FDA this spring after nearly two years at the helm. During his tenure, Gottlieb advanced a number of prescription drug policies, including to push the FDA to speed up generic drug approvals and use its powers to encourage wider use of biosimilars, or copycat versions of complex and often costly biologic drugs.
Biosimilar manufacturers, including Pfizer, have complained about roadblocks stalling biosimilars from becoming widely used. Having Gottlieb to advise the company could help Pfizer, one of the largest biopharmaceutical companies, navigate the landscape.
CEO Albert Bourla, who succeeded Ian Read on January 1, shuffled the company's senior management team last year and is leading the effort to restructure the pharmaceutical giant into a more nimble company. Pfizer announced plans last July to reorganize into three units, separating out its consumer healthcare business that it had been trying to sell.
"We are fortunate to have Dr. Gottlieb join Pfizer's Board of Directors," Pfizer Executive Chairman and former CEO Ian Read said in a statement. "Scott's expertise in health care, public policy and the industry will be an asset to our company and enable our shareholders to continue to benefit from a Board representing a balance of experience, competencies and perspectives."
Since leaving the FDA, Gottlieb has returned to the American Enterprise Institute as a resident fellow and as a special partner at venture capital firm New Enterprise Associates, where he worked before joining the FDA. He also joined CNBC as a contributor.
Disclosure: Scott Gottlieb is a CNBC contributor.
—CNBC's Berkeley Lovelace Jr. contributed to this report.